Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
ICON Public Limited Company is a diagnostics & research business based in the US. ICON Public Limited Company shares (ICLR) are listed on the NASDAQ and all prices are listed in US Dollars. ICON Public Limited Company employs 37,960 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $250.39 |
|---|---|
| 52-week range | $168.76 - $313.00 |
| 50-day moving average | $281.73 |
| 200-day moving average | $249.50 |
| Wall St. target price | $317.50 |
| PE ratio | 85.7264 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $2.94 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $250.39 from 2022-01-25
| 1 week (2022-01-19) | -2.59% |
|---|---|
| 1 month (2021-12-23) | -18.69% |
| 3 months (2021-10-26) | -12.19% |
| 6 months (2021-07-26) | 15.93% |
| 1 year (2021-01-26) | 17.50% |
|---|---|
| 2 years (2020-01-24) | 43.12% |
| 3 years (2019-01-25) | 84.65% |
| 5 years (2017-01-26) | 207.98% |
Valuing ICON Public Limited Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ICON Public Limited Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
ICON Public Limited Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 86x. In other words, ICON Public Limited Company shares trade at around 86x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
ICON Public Limited Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.9428. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into ICON Public Limited Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
ICON Public Limited Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $661.4 million.
The EBITDA is a measure of a ICON Public Limited Company's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $4.4 billion |
|---|---|
| Operating margin TTM | 10.77% |
| Gross profit TTM | $819.9 million |
| Return on assets TTM | 2.83% |
| Return on equity TTM | 3.68% |
| Profit margin | 4.09% |
| Book value | $97.90 |
| Market capitalisation | $20.1 billion |
TTM: trailing 12 months
We're not expecting ICON Public Limited Company to pay a dividend over the next 12 months.
ICON Public Limited Company's shares were split on a 2:1 basis on 12 August 2008. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your ICON Public Limited Company shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for ICON Public Limited Company shares which in turn could have impacted ICON Public Limited Company's share price.
Over the last 12 months, ICON Public Limited Company's shares have ranged in value from as little as $168.76 up to $313. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ICON Public Limited Company's is 0.8875. This would suggest that ICON Public Limited Company's shares are less volatile than average (for this exchange).
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. The company's clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional solutions, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON has an agreement with Evergreen Therapeutics, Inc. to conduct Phase II clinical trial for COVID-19 drug candidate.
Bitcoin breached the $40,000 price level and may plummet lower as Russia signals a potential ban.
Cardano’s first metaverse project is available to investors now — if you can find a piece of digital land on sale. Plots sold fast despite the project’s early stage limitations.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.